Effects of Dietary Fiber on Affective Processes

Sponsor
KU Leuven (Other)
Overall Status
Completed
CT.gov ID
NCT04522258
Collaborator
(none)
70
1
2
18.3
3.8

Study Details

Study Description

Brief Summary

The effects of dietary fiber on psychobiological processes are examined in a sample of healthy volunteers.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Dietary fiber
  • Dietary Supplement: Placebo
N/A

Detailed Description

The study is an interventional triple-blind, placebo-controlled, parallel group design with 2 arms (placebo, dietary fiber). Healthy male participants adhere to their normal eating habits for the duration of the study (32 days). At the baseline study visit, measurements are taken in the lab, including biological samples and psychophysiological measurements. Participants then consume placebo or dietary fiber for 4 weeks and revisit the lab on day 32 for a second measurement of the outcomes of interest. Specifically, we investigate the effect of dietary fiber on affective processing, including stress sensitivity and fear-related processes (e.g. extinction learning). Volunteers also respond to questionnaires in relation to mood and GI symptoms, and provide biological samples (saliva, blood, faecal, and urine samples) for analysis of cortisol levels, circulating short chain fatty acids and serum BDNF, faecal SCFA and microbiota composition, and intestinal permeability, respectively.

Study Design

Study Type:
Interventional
Actual Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
Participants, investigators, and personnel involved in data analyses are blinded to the intervention. Unblinding occurs after all data has been collected AND analysed.
Primary Purpose:
Basic Science
Official Title:
Effects of Dietary Fiber on Affective Processes
Actual Study Start Date :
May 2, 2019
Actual Primary Completion Date :
Nov 8, 2020
Actual Study Completion Date :
Nov 8, 2020

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Placebo

Refined cereal flour

Dietary Supplement: Placebo
Refined cereal flour

Active Comparator: Dietary fiber

Fermentable cereal bran

Dietary Supplement: Dietary fiber
Fermentable cereal bran

Outcome Measures

Primary Outcome Measures

  1. Stress sensitivity (cortisol) [through study completion, on average 1 year and 5 months]

    Induction of cognitive, physical, and social stress using Maastricht Acute Stress Test. Stress hormone cortisol is quantified by gathering multiple saliva samples throughout the stress induction and recovery during both pre-intervention and post-intervention visit.

Secondary Outcome Measures

  1. Stress sensitivity (subjective) [through study completion, on average 1 year and 5 months]

    Induction of cognitive, physical, and social stress using Maastricht Acute Stress Test. Participant rate how much stress, discomfort, and pain they feel on a 10-cm visual analogue scale, with higher values indicating greater stress, discomfort, and pain. This is done prior to stress induction, in the middle, and at the end at both pre- and post-intervention visits.

  2. Cortisol awakening response [through study completion, on average 1 year and 5 months]

    Measuring chronic stress by quantifying cortisol in morning samples (5 samples taken form the moment of waking every 15 minutes for 1 hour) on the morning of the pre- and post-intervention visits.

  3. Fear [through study completion, on average 1 year and 5 months]

    Exploring fear-related processes (conditioning, extinction, recall, and renewal) by means of a computerised task. Fear response is measured using skin conductance, and a skin conductance response is calculated.

  4. Fear (subjective) [through study completion, on average 1 year and 5 months]

    Exploring fear-related processes (conditioning, extinction, recall, and renewal) by means of a computerised task. Fear response is measured subjectively by asking participants to indicate their expectancy of an aversive stimulus.

  5. Positive and Negative Affect Schedule (PANAS) [through study completion, on average 1 year and 5 months]

    Assessing ratings on the subscales of PANAS, positive and negative affect. PA subscale scores range between 10-50, with higher scores indicating better outcome. NA subscale scores range between 10-50, with higher scores indicating worse outcome.

  6. Perceived Stress Scale (PSS) [through study completion, on average 1 year and 5 months]

    Assessing ratings on PSS PSS scores range between 0-40 with higher scores indicating worse outcome.

  7. Depression, anxiety, and stress scales (DASS-21) [through study completion, on average 1 year and 5 months]

    Assessing ratings on the subscales of DASS-21, depression, anxiety, and stress subscales. Higher scores on these subscales indicates a worse outcome. Normal (depression: 0 - 4; anxiety: 0 - 3; stress: 0 - 7), Mild (depression: 5 - 6; axiety: 4 - 5; stress: 8 - 9), Moderate (depression: 7 - 10; anxiety: 6 - 7; stress: 10 - 12), Severe (depression: 11 - 13; anxiety: 8 - 9; stress: 13 - 16), Extremely Severe (depression: 14 +; anxiety: 10 +; stress: 17 +).

  8. Leiden Index of Depression Sensitivity-Revised (LEIDS-R) [through study completion, on average 1 year and 5 months]

    Assessing ratings on the subscales of LEIDS-R and its total score. This is a self-report on cognitive reactivity comprised of 34 items with six subscales. Hopelessness/suicidality; Acceptance/Coping; Aggression; Control/Perfectionism; Risk Aversion; Rumination.

  9. Gastrointestinal symptom rating scale (GSRS) [through study completion, on average 1 year and 5 months]

    Assessing ratings on the subscales of GSRS and its total score. It has 5 subscales (Reflux, Diarrhea, Constipation, Abdominal Pain, and Indigestion Syndrome). Subscale scores range from 1 to 7 and higher scores indicates a worse outcome.

  10. Serum SCFA [through study completion, on average 1 year and 5 months]

    Quantification of serum SCFA (μM) at pre- and post-intervention

  11. Faecal SCFA [through study completion, on average 1 year and 5 months]

    Quantification of faecal SCFA in samples provided at pre- and post-intervention

  12. Intestinal permeability [through study completion, on average 1 year and 5 months]

    Conducting a lactulose and mannitol test before and after the intervention

  13. Serum BDNF [1 year and 5 months]

    Quantification of fasting serum BDNF levels (µg/mL)

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 40 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Male participants

  • Age range 20-40 years

  • BMI range 18.5-27

  • Dutch or English as native-language

Exclusion Criteria:
  • previous or current neurological, psychiatric, gastrointestinal or endocrine disorders, or other relevant medical history

  • current or recent regular medication use

  • previous or current substance/alcohol dependence or abuse (> 2 units per day/14 units per week)

  • one or more diagnoses based on the mini-international neuropsychiatric interview

  • smoking

  • night-shift work

  • adherence to vegan or vegetarian diets

  • use of pre- or probiotics within one month preceding the study

  • use of antibiotics within 3 months preceding the study

  • Habitual diet not exceeding consumption of 25 g of dietary fiber per day

  • previous experience with one of the tasks used in the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 UZ Leuven/Stresslab Leuven I Am Not In The U.S. Or Canada Belgium 3000

Sponsors and Collaborators

  • KU Leuven

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kristin Verbeke, Prof. Dr. Kristin Verbeke, KU Leuven
ClinicalTrials.gov Identifier:
NCT04522258
Other Study ID Numbers:
  • S62344
First Posted:
Aug 21, 2020
Last Update Posted:
Jan 7, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Jan 7, 2021